Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. by Satoh, M. et al.
Proc. Natl. Acad. Sci. USA
Vol. 92, pp. 10934-10938, November 1995
Immunology
Anti-nuclear antibody production and immune-complex
glomerulonephritis in BALB/c mice treated with pristane
(systemic lupus erythematosus/lupus nephritis/autoantibodies/autoimmunity/small nuclear ribonucleoproteins)
MINORU SATOH*, ANIL KUMARt, YASHPAL S. KANWARt, AND WESTLEY H. REEVES*t
*Departments of Medicine and Microbiology/Immunology, Thurston Arthritis Research Center and University of North Carolina Lineberger Comprehensive
Cancer Center, University of North Carolina, Chapel Hill, NC 27599-7280; and tDepartment of Pathology, Northwestern University Medical School,
Chicago, IL 60611
Communicated by Maclyn McCarty, The Rockefeller University, New York, NY, August 10, 1995
ABSTRACT The pathogenesis of systemic lupus erythe-
matosus is thought to be primarily under genetic control, with
environmental factors playing a secondary role. However, it
has been shown recently that intraperitoneal injection- of
pristane (2,6,10,14-tetramethylpentadecane) induces autoan-
tibodies typical of lupus in BALB/c mice, a strain not usually
considered to be genetically susceptible to the disease. In this
study, the induction of autoimmune disease by pristane was
investigated. BALB/c mice receiving pristane were tested for
autoantibody production and histopathological evidence of
glomerulonephritis. Six of 11 mice developed IgM anti-single-
stranded DNA antibodies shortly after receiving pristane and
4 developed IgM anti-histone antibodies, but anti-double-
stranded DNA antibodies were absent. IgG anti-DNA and
anti-histone antibodies were absent. In contrast, the lupus-
associated anti-nuclear ribonucleoprotein/Sm and anti-Su
autoantibodies produced by these mice were predominantly
IgG. In addition to autoantibodies, most of the mice developed
significant proteinuria. Light microscopy of the kidney
showed segmental or diffuse proliferative glomerulonephritis.
Electron microscopy showed subepithelial and mesangial
immune-complex deposits and epithelial foot process efface-
ment. Immunofluorescence revealed striking glomerular
deposition of IgM, IgG, and C3 with a mesangial or mesan-
giocapillary distribution. Thus, pristane induces immune-
complex glomerulonephritis in association with autoantibod-
ies typical of lupus in BALB/c mice. These data support the
idea that lupus is produced by an interplay of genetic and
environmental factors and that unlike the MRL or (NZB x
W)F1 mouse models, in which genetic susceptibility factors are
of primary importance, environmental factors are of consid-
erable importance in the autoimmune disease of pristane-
treated BALB/c mice.
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disease characterized by anti-nuclear antibodies, im-
mune-complex glomerulonephritis, arthritis, and other mani-
festations. Anti-double-stranded (ds) DNA autoantibodies are
highly specific for SLE and may play a key role in the
pathogenesis of immune-complex nephritis in lupus (1, 2).
However, autoantibodies to glomerular antigens (3) and/or
dysregulated cytokine production (4, 5) may also be involved.
Human SLE is influenced strongly by major histocompatibility
complex-linked and -nonlinked genes (6-8). Multiple genetic
loci that accelerate the onset of autoantibody production
and/or nephritis also have been identified in murine lupus
models (9, 10). The importance of environmental factors in the
pathogenesis of lupus is less clear. However, the role of
environmental exposures in autoantibody production is un-
derscored by the recent demonstration that intraperitoneal
(i.p.) injection of pristane (2,6,10,14-tetramethylpentadecane)
induces autoantibodies characteristic of SLE, including anti-Su
and anti-nuclear ribonucleoprotein (nRNP)/Sm, in BALB/c
mice, a strain not usually considered to be predisposed to
autoimmunity (11). Titers of these autoantibodies are compa-
rable to those found in MRL/lpr mice (12). The present data
show that in addition to IgG anti-Su and anti-nRNP/Sm
autoantibodies, pristane induces IgM anti-single-stranded (ss)
DNA, anti-histone antibodies, and immune-complex glomer-
ulonephritis in the "nonautoimmune" BALB/c strain.
MATERIALS AND METHODS
Administration ofPristane. Eleven 4- to 5-month-old and 10
2.5-month-old female BALB/c ByJ mice (The Jackson Lab-
oratory) received a single i.p. injection of 0.5 ml of pristane
(Sigma) (11). Sera were obtained at 1, 2, and 4 weeks and
monthly thereafter. Urine samples were tested monthly for
protein concentration by using Albustix reagent strips (Miles).
ELISAs for Anti-nRNP/Sm, Su, ssDNA, and Histone Au-
toantibodies. Anti-Su and anti-nRNP/Sm antigen-capture
ELISAs were performed as described (12) with 1:250 diluted
murine serum and alkaline phosphatase-conjugated goat anti-
mouse IgG or IgM antibodies. Antibodies to heat-denatured
calf thymus DNA (ssDNA, from Sigma) and to total calf
thymus histones (United States Biochemical) were detected by
ELISAs as described (13, 14) with a 1:500 dilution of murine
sera and alkaline phosphatase-conjugated goat anti-mouse
IgG or IgM antibodies.
Light and Electron Microscopy. Six months after receiving
pristane, BALB/c and control mice not receiving pristane
were anesthetized and fixed by perfusion through the left
ventricle (15). The inferior vena cava was nicked below the
renal veins, and 20 ml of saline was perfused slowly, followed
by 10 ml of 2.5% (vol/vol) glutaraldehyde in 0.1 M sodium
cacodylate, pH 7.4/4 mM CaCl2. For light microscopy, 3-,um
sections of aldehyde-fixed renal cortex were stained with
hematoxylin and eosin as described (16). For electron micros-
copy, aldehyde-fixed renal tissue was postfixed with osmium
tetroxide, dehydrated in ethanol, and embedded in Epon 812.
Thin sections (60 nm) were stained with lead citrate and uranyl
acetate and examined by electron microscopy (16).
Immunofluorescence. Kidneys were excised from pristane-
primed or control mice and snap-frozen in isopentane chilled
in liquid N2. Cryostat sections (4 ,um) were stained with a 1:40
dilution of fluorescein isothiocyanate (FITC) or rhodamine-
conjugated goat anti-mouse IgM, IgG, IgGl, IgG2a, IgG2b, or
IgG3 antibodies (Southern Biotechnology Associates) or with
FITC-conjugated rabbit anti-mouse C3 antiserum (Organon
Abbreviations: nRNP, nuclear ribonucleoprotein; SLE, systemic lupus
erythematosus; ds, double stranded; ss, single stranded; IL, inter-
leukin.
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Teknika-Cappel) at the same dilution. Stained sections were
examined with an epifluorescence UV microscope with FITC
and rhodamine filters.
RESULTS
SLE is associated with autoantibodies to protein or protein-
nucleic acid complexes (17), including the Ul small nRNP
(anti-nRNP and Sm antibodies) (18), Su antigen (19, 20), and
nucleosomes (anti-DNA and anti-histone antibodies) (21). We
have shown (11) that anti-Su and anti-nRNP/Sm antibody
responses develop in BALB/c mice, a "nonautoimmune"
strain, within several months after a single i.p. pristane injec-
tion (11). The present study addresses the question of whether
autoantibody production induced by pristane is associated with
autoimmune disease compatible with SLE.
IgG Anti-Su and Anti-nRNP/Sm Autoantibodies. IgG an-
ti-Su antibodies appeared in the sera of 5 of 11 BALB/c mice
2-3 months after pristane injection (Fig. 1D). IgM anti-Su
antibodies were detected at a low level in only 1 of 5 mice (Fig.
1B), and there was little evidence for IgM to IgG class
switching. Six of the mice never developed anti-Su antibodies.
IgM and IgG anti-nRNP/Sm antibodies exhibited a similar
pattern (Fig. 1 A and C), although their onset was delayed
compared with anti-Su antibodies, as reported (11). As with
anti-Su, IgG antibodies dominated the immune response to
nRNP/Sm, with little evidence for class switching. The unex-
plained lack of autoantibody class switching in lupus has been
noted (22). Seven of 11 mice developed anti-nRNP/Sm by 6
months after pristane injection, and there was little or no
correlation between anti-Su and anti-nRNP/Sm antibody pro-
duction by individual mice. Analysis of the isotypes of anti-Su
and anti-nRNP/Sm antibodies by ELISA showed that IgGl,
IgG2a, IgG2b, and IgG3 autoantibodies of both specificities
were present (data not shown).
IgM Anti-DNA and Anti-Histone Antibodies. Anti-ssDNA
antibody production contrasted markedly with that of anti-Su
and nRNP/Sm. IgM anti-ssDNA antibodies appeared in 4 of
11 BALB/c mice within 1 month of pristane injection (Fig.
2A), and in two more mice by 3 months. In a second experi-
ment, they were found in 4 of 10 sera as early as 1-2 weeks after










anti-Su/nRNP/Sm antibodies, IgG anti-ssDNA antibodies
were undetectable (Fig. 2C). There was no apparent relation-
ship between IgM anti-ssDNA and IgM or IgG anti-Su or
nRNP/Sm autoantibody production (cf. Figs. 1 and 2). Anti-
dsDNA antibodies were absent in all sera by the Crithidia
luciliae kinetoplast staining method.
The production of IgM anti-histone antibodies resembled
anti-ssDNA autoantibody production in its early onset and the
absence of IgG class antibodies (Fig. 2 B and D). There was no
association of anti-histone with anti-Su or anti-nRNP/Sm
antibodies. Unexpectedly, there was also no relationship be-
tween anti-ssDNA and anti-histone antibody production (in 6
of 11 and 3 of 11 mice, respectively), despite previous evidence
that nucleosomes (DNA plus histones) are a major target of
immune responses in murine lupus (21). Thus, the data suggest
that BALB/c mice produce the lupus-associated autoantibod-
ies anti-Su and anti-nRNP/Sm, as well as less disease-specific
autoantibodies such as anti-ssDNA and anti-histone. Whereas
the anti-Su/nRNP/Sm antibody responses were predomi-
nantly IgG, the anti-ssDNA and anti-histone responses were
limited to IgM. In view of the association of autoantibody
production with nephritis in SLE, kidneys of the mice were
examined for immune-complex glomerulonephritis.
Development of Immune-Complex Glomerulonephritis.
Light microscopy of kidney sections from five mice injected
with pristane 6 months earlier revealed segmental or diffuse
proliferative glomerular lesions (Fig. 3A), consistent with
World Health Organization class III, IV, and V lupus nephritis
(23). Proliferation was mainly related to an increase in me-
sangial cells. In addition, the epithelial and endothelial cells
were hypertrophic and capillary loops were thickened. A mild
to moderate influx of monocytes was seen in the glomerular
capillaries. These changes were not apparent in the glomeruli
of control mice (cf. Fig. 3 A vs. C), which exhibited the usual
glomerular morphology (24). Electron microscopy showed
irregular thickening of the glomerular basement membrane,
subepithelial dense deposits, and epithelial foot process ef-
facement in pristane-treated mice (Fig. 3B) but not in control
mice (Fig. 3D). The mesangial matrix and mesangial cells were
increased, and scattered mesangial deposits were also noted.
Immunofluorescence studies reinforced the morphologic find-
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FIG. 1. Time course of anti-nRNP/Sm and Su antibody production. Levels of IgM (A and B) and IgG (C and D) anti-nRNP/Sm (A and C)
and anti-Su (B and D) antibodies in sera from 11 BALB/c mice injected i.p. with pristane were determined by antigen-capture ELISA. OD405 X
10-3 iS plotted as a function of time (months) after pristane was injected.
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FIG. 2. Time course of anti-ssDNA and anti-histone antibody production. Levels of IgM (A and B) and IgG (C and D) anti-ssDNA (A and C)
and anti-histone (B and D) antibodies in sera from 11 BALB/c mice injected i.p. with pristane were determined by ELISA. OD405 x 10-3 is plotted
as a function of time (months) after pristane was injected.
vealed mesangial or mesangiocapillary reactivities for IgG, glomeruli from control mice were negative for IgG and showed
IgM, and C3 (Fig. 4 H, M, and N, respectively), whereas very weak reactivity for IgM and C3 (Fig. 4 A, F, and G).
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FIG. 4. Immunofluorescence microscopy. Photomicrographs of glomeruli from a control mouse (A-G) or a BALB/c mouse injected 6 months
previously with pristane (H-N), stained with specific goat anti-mouse immunoglobulin or complement antibodies. Note the predominant mesangial
or mesangiocapillary distribution of the immune complex deposits in the pristane-induced glomerular lesions. (A and H) Anti-IgG. (B and I)
Anti-IgGl. (C and J) Anti-IgG2a. (D and K) Anti-IgG2b. (E and L) Anti-IgG3. (F and M) Anti-IgM. (G and N) Anti-C3. (x 120.)
Staining with isotype-specific second antibodies revealed glo-
merular immunoreactivity with IgGl, IgG2a, IgG2b, and IgG3
in the pristane-primed (Fig. 4 I-L, respectively) but not control
(Fig. 4 B-E) mice. Urinalysis revealed 1-3+ proteinuria (30-
300 mg/dl) in all mice at 6 months after pristane injection.
Proteinuria was <1 + (30 mg/dl) in control mice.
DISCUSSION
Autoantibodies associated with SLE are produced by BALB/c
mice treated with pristane (11, 12) and by pristane-primed
(NZB x BALB/c)F1 mice injected with NZB myeloma cells
(25). In addition, -10% of paraproteins produced by pristane-
induced mouse myelomas are reactive with nucleic acids
and/or dinitrophenyl derivatives (26), and pristane induces
rheumatoid factor and autoantibodies to type II collagen and
hsp70 (27, 28). The present studies indicate that pristane also
causes renal changes in BALB/c mice compatible with lupus
nephritis.
Induction of Anti-DNA and Anti-Histone Antibodies. In
contrast to IgG anti-Su/nRNP/Sm autoantibodies, which ap-
pear 2-6 months after pristane injection (Fig. 1 and refs. 11
and 12), anti-ssDNA and anti-histone antibodies appeared as
early as 1-4 weeks (Fig. 2) and were exclusively IgM class. The
absence of IgG anti-ssDNA or anti-histone antibodies may
imply that these specificities develop by a different mechanism
than was responsible for the IgG anti-Su/nRNP/Sm antibod-
ies. Low-affinity polyreactive anti-ssDNA antibodies, primar-
ily IgM class, are produced by the Bi (CD5+) B-cell subset,
whereas high-affinity IgG autoantibodies are produced mainly
by the CD5- subset (29-31). Of note, the Bi subset is highly
enriched in the peritoneal cavity and is expanded in BALB/c
and NZB mice (32), raising the possibility that the IgM
anti-ssDNA and anti-histone antibodies induced by i.p.
pristane injection were derived from that subset. Moreover,
preliminary competitive binding experiments suggest that the
IgM anti-ssDNA antibodies have low affinity (data not shown).
In contrast, the anti-Su/nRNP/Sm autoantibodies induced by
pristane were predominantly of the T-cell-dependent sub-
classes IgGl, IgG2a, or IgG2b (11, 12). In view of the
suggestion that antibody production by the CD5+ subset may
be largely T-cell independent (33), the anti-Su/nRNP/Sm
antibodies may have been derived from CD5- B cells. How-
ever, further studies are needed to answer this question
definitively.
Pathogenesis of Glomerulonephritis in Pristane-Treated
Mice. There is considerable evidence that anti-DNA antibod-
ies are involved in the pathogenesis of glomerulonephritis (1,
2,34). However, although some anti-ssDNA antibodies may be
pathogenic (34, 35), the bulk of evidence suggests that anti-
dsDNA antibodies are more relevant to the pathogenesis of
lupus nephritis (36). Thus, the absence of anti-dsDNA anti-
bodies in the sera of pristane-treated BALB/c mice suggests
that the severe immune complex nephritis in these mice was
not mediated by anti-DNA antibodies. This interpretation is
supported further by the fact that some anti-DNA-antibody-
negative mice also developed glomerulonephritis. However,
we cannot exclude the possibility that polyclonal activation of
CD5+ B cells is essential for the later development of high-
affinity IgG autoantibodies and lupus-like disease (37) in
pristane-treated mice, even though the IgM anti-ssDNA an-
tibodies produced by these cells are not pathogenic. It is of
interest, in this regard, that CD5+ B cells are an important
source of interleukin (IL) 10 (38), a cytokine that has been
implicated in the pathogenesis of glomerulonephritis (39).
In addition to promoting plasmacytoma growth in mice
treated with pristane (40-42), IL-6 may play a role in me-
sangial proliferative and membranoproliferative glomerulone-
phritis (43, 44), and murine lupus nephritis (4, 5). Since the
nephritis in pristane-primed BALB/c mice was similar histo-
logically to that in the (NZB x W)F1 model, it is possible that
increased IL-6 levels exacerbated glomerulonephritis in mice
receiving pristane. IL-10 also exacerbates glomerulonephritis
in (NZB x W)F1 mice (39). It will be of interest to investigate
whether increased IL-6 or IL-10 production, the latter possibly
due to the CD5+ B-cell expansion in BALB/c mice (38), is
involved in the striking mesangial cell proliferation seen in
both the pristane and (NZB x W)F1 models.
Relevance to Idiopathic SLE. These studies provide evi-
dence that the autoimmune syndrome induced by pristane in
BALB/c mice resembles idiopathic SLE in humans. As in
human SLE, mice injected with pristane develop anti-nuclear
antibodies recognizing a small subset of antigens including the
Su antigen, components of U small nRNPs, ssDNA, and
histones. The titers of anti-Su and anti-nRNP/Sm autoanti-
bodies produced by pristane-primed BALB/c mice are at least
as high as seen in MRL/lpr mice (12). However, unlike human
SLE, dsDNA, Ro (SS-A), and La (SS-B) are not prominent
autoantigens in this model.
The development of glomerular lesions reminiscent of lupus
nephritis (Figs. 3 and 4) and autoantibodies characteristic of
SLE suggests that environmental stimuli may precipitate au-
toimmune disease in mice not genetically predisposed to SLE.
That idea is also supported by the induction of autoantibodies,
and in some cases glomerular lesions, by HgCl2 or lipopoly-
saccharide (45-48). The relatively high concentration of
pristane in certain food items (49) raises the possibility that
environmental exposure to pristane or its metabolites might
contribute to the pathogenesis of some cases of human SLE.
Ingestion of pristane causes amyloidosis in mice (50), but it is
not known whether autoimmunity develops after oral expo-
sure. It should be noted that the renal lesions in mice receiving
pristane i.p. were not compatible with amyloidosis.
Multiple genes contribute to SLE susceptibility (8, 9), and
environmental factors are generally relegated to a secondary
role. If, as suggested by our data, pristane treatment bypasses
Immunology: Satoh et al.
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or replaces the effect of one or more genetic susceptibility
factors, then understanding the pathogenesis of pristane-
induced lupus-like syndrome may simplify the identification of
genes conferring susceptibility to idiopathic lupus. Further-
more, the induction by pristane of a lupus-like disease in other
"normal" strains of mice in addition to BALB/c (data not
shown) suggests that the notion that SLE is primarily a genetic
disease may be overly simplistic. Our data suggest that in some
instances, such as the MRL or (NZB x W)F1 mouse models,
genetic susceptibility factors are primarily responsible for SLE
(9), whereas in other cases, such as the pristane model,
environmental factors may be of considerable importance. The
two situations may be analogous to familial and sporadic lupus,
respectively. Intermediates between the two extreme cases may
exist. It will be of interest in the future to examine whether the
genetic and environmental factors influence susceptibility to
SLE independently or through actions on a common pathway.
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